Yan Zhang
张岩
Yan Zhang is the co-founder and CEO of MingMed (因明生物), a biotech company developing first-in-class drugs. He was in that role as of 2021, when he represented the company in two funding announcements: a nearly $60 million Series A in March 2021 and a nearly $50 million Series A+ in September 2021, both reported by 高榕创投 (Gaorong Capital) . Elsewhere's corpus does not cover this subject beyond those funding announcements.
AI-generated — may contain errors, please verify.
Yan ZhangPerson
张岩
渲染中…
Mentioned in 3 articles
Coverage
Bolt Interview | Notta Founder Yan Zhang on Localization Strategies for AI SaaS Products in Japan
Rooted in Place, Returning to Place
线性资本·MingMed Completes Nearly $50 Million Series A+ Round to Accelerate Clinical Trials for Key Pipeline Candidates
Accelerating the development of globally leading first-in-class drugs.
高榕创投·Inventage Biotech Closes Nearly $60 Million Series A to Develop Globally Leading First-in-Class Drugs
First in China, Best in the World
高榕创投·
